Testing a new immune-boosting drug for advanced lung cancer

Plain-English translation of NCT06116786 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Carcinoma, Non-small-Cell Lung research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new drug called , which works by activating your immune system to help fight advanced lung cancer. The study will test this medication alone first, then in combination with another immunotherapy drug and radiation therapy. Researchers want to find the safest and most effective dose, and to learn whether combining these treatments works better than using them separately.

Advanced lung cancer is difficult to treat, especially after standard therapies stop working. This medication is designed to unlock your immune system's natural ability to attack cancer cells, and early research suggests it may work better when combined with other immunotherapies and radiation.

Do you qualify?

You likely qualify if…

you have been diagnosed with stage 3B or stage 4 non-small cell lung cancer
your cancer has specific genetic mutations and you've already tried all approved targeted therapies (if enrolling in Part 1)
your cancer does not have certain genetic mutations (if enrolling in Part 2)
you have received previous immunotherapy and chemotherapy treatment (depending on which part of the study you join)
your heart, liver, and kidneys are functioning well enough to tolerate this treatment

You likely don't qualify if…

you have cancer that has spread to your brain or central nervous system
you have an active autoimmune disease requiring ongoing treatment
you currently have an active infection
you have had an organ transplant or stem cell transplant in the past
you are unable to follow the study schedule or have serious medical conditions that would make participation unsafe

What participation looks like

The trial has two main parts. First, researchers will test different doses of the medication alone, then combined with another immunotherapy drug to find the right dose. In the second part, participants will receive the selected dose combined with the second immunotherapy drug and radiation therapy. You'll have screening visits to confirm you qualify, regular treatment visits (likely weekly or monthly depending on the phase), and follow-up appointments to monitor your health and how well the treatment is working.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Trial locations(15 sites)

United States

City of Hope 1, Newnan, Georgia

Hackensack University Medical Center, Hackensack, New Jersey

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

Providence Portland Medical Center, Portland, Oregon